DE68929507D1 - Rekombinante mykobakterielle expressions-träger sowie deren verwendung - Google Patents

Rekombinante mykobakterielle expressions-träger sowie deren verwendung

Info

Publication number
DE68929507D1
DE68929507D1 DE68929507T DE68929507T DE68929507D1 DE 68929507 D1 DE68929507 D1 DE 68929507D1 DE 68929507 T DE68929507 T DE 68929507T DE 68929507 T DE68929507 T DE 68929507T DE 68929507 D1 DE68929507 D1 DE 68929507D1
Authority
DE
Germany
Prior art keywords
mycobacteria
recombinant
mycobacterial
vector
coli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68929507T
Other languages
English (en)
Other versions
DE68929507T2 (de
Inventor
Barry R Bloom
Ronald W Davis
William R Jacobs Jr
Richard A Young
Robert N Husson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Albert Einstein College of Medicine
Leland Stanford Junior University
Original Assignee
Whitehead Institute for Biomedical Research
Albert Einstein College of Medicine
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research, Albert Einstein College of Medicine, Leland Stanford Junior University filed Critical Whitehead Institute for Biomedical Research
Application granted granted Critical
Publication of DE68929507D1 publication Critical patent/DE68929507D1/de
Publication of DE68929507T2 publication Critical patent/DE68929507T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE68929507T 1988-07-07 1989-07-07 Rekombinante mykobakterielle expressions-träger sowie deren verwendung Expired - Fee Related DE68929507T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21639088A 1988-07-07 1988-07-07
US22308988A 1988-07-22 1988-07-22
US223089 1988-07-22
US07/361,944 US5504005A (en) 1987-03-02 1989-06-05 Recombinant mycobacterial vaccine
PCT/US1989/002962 WO1990000594A2 (en) 1988-07-07 1989-07-07 Recombinant mycobacterial expression vehicles and uses therefor
US216390 1994-03-23
US361944 1994-12-22

Publications (2)

Publication Number Publication Date
DE68929507D1 true DE68929507D1 (de) 2004-01-29
DE68929507T2 DE68929507T2 (de) 2004-09-23

Family

ID=27396269

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68929507T Expired - Fee Related DE68929507T2 (de) 1988-07-07 1989-07-07 Rekombinante mykobakterielle expressions-träger sowie deren verwendung

Country Status (8)

Country Link
US (5) US5504005A (de)
EP (1) EP0424437B1 (de)
JP (2) JP3485916B2 (de)
AT (1) ATE256730T1 (de)
AU (1) AU3867789A (de)
CA (1) CA1339526C (de)
DE (1) DE68929507T2 (de)
WO (1) WO1990000594A2 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
JP2903414B2 (ja) * 1989-05-31 1999-06-07 味の素株式会社 抗酸菌分泌発現ベクター及び抗酸菌
DE69027956T2 (de) * 1989-05-31 1997-03-06 Ajinomoto Kk Sekretorische Expressionsvektoren für Mycobakterien sowie Transformanten
AU5848090A (en) * 1989-06-19 1991-01-08 Whitehead Institute For Biomedical Research Vector-mediated genomic insertion and expression of dna in bcg
EP0517751A4 (en) * 1990-02-26 1993-03-31 Commonwealth Scientific & Industrial Research Organisation ( C.S.I.R.O. ) Shuttle plasmid for escherichia coli and mycobacteria
CA2045842A1 (en) * 1990-07-16 1992-01-17 William R. Jacobs Dna capable of site-specific integration into mycobacteria
GB9015888D0 (en) * 1990-07-19 1990-09-05 Smithkline Biolog Vectors
US5637303A (en) * 1990-10-25 1997-06-10 Commonwealth Scientific And Industrial Research Organisation Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination
WO1992007582A1 (en) * 1990-10-25 1992-05-14 Commonwealth Scientific And Industrial Research Organisation Corynebacteria and related organisms as vaccine vectors
AU643842B2 (en) * 1990-10-25 1993-11-25 Commonwealth Scientific And Industrial Research Organisation Corynebacteria and related organisms as vaccine vectors
AU2221992A (en) * 1991-06-06 1993-01-08 Med Immune, Inc. Induction of immune response against tetanus toxin through administration of mycobacteria expressing tetanus toxin or fragments
EP0587775A4 (de) * 1991-06-06 1994-11-02 Medimmune Inc Induktion der ctl-antwort durch in mycobakterien exprimierte fremde antigene.
JPH06511145A (ja) * 1991-06-13 1994-12-15 アルバート　アインシュタイン　カレッジ　オブ　メディシン、ア　ディビジョン　オブ　イェシーバ　ユニバーシティ ミコバクテリア内での挿入突然変異
US6566121B1 (en) * 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
EP0521220A1 (de) * 1991-06-14 1993-01-07 Institut Pasteur Immunogene rekombinante Actinomycetale
US6300061B1 (en) 1992-02-07 2001-10-09 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial species-specific reporter mycobacteriophages
US5750384A (en) * 1992-02-07 1998-05-12 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University L5 shuttle phasmids
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
JPH08510756A (ja) * 1993-06-04 1996-11-12 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ストレス蛋白質とその使用
AU1097795A (en) 1993-11-23 1995-06-13 Regents Of The University Of California, The Abundant extracellular products and methods for their production and use
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
FR2720076B1 (fr) 1994-05-20 1996-08-02 Inst Nat Sante Rech Med Vecteurs navettes pour l'introduction d'ADN dans des mycobactéries et utilisation de ces bactéries comme vaccins.
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU774535B2 (en) * 1995-10-20 2004-07-01 Actogenix Nv Delivery of biologically active polypeptides
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
JP2001512435A (ja) * 1997-01-21 2001-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 豊富な細胞外産物ならびにそれらの産生および使用方法
EP1047451A1 (de) * 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Verwendung von hitzeshockproteinen zur verabreichung von einheiten in zellen
JP4198315B2 (ja) 1997-08-05 2008-12-17 ヌベンタ バイオファーマスティカル コーポレイション Ｈｐｖ抗原およびストレスタンパク質またはこれらのタンパク質の発現が可能な発現ベクターを含む組成物によって誘起されるｈｐｖ抗原に対する免疫応答
EP0934421A1 (de) * 1997-08-06 1999-08-11 Laboratorio Medinfar-Produtos Farmaceuticos LDA. Dna-integrierung in das genom von mycobakterium spp. durch trans-komplementierung mit hilfe eines zielortgerichteten integrationssystems
US6322991B1 (en) * 1997-08-21 2001-11-27 York University High-throughput screens for enzyme inhibitors
EP0902086A1 (de) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberkolose Impfstoff
US5972700A (en) * 1997-09-26 1999-10-26 Albert Einstein College Of Medicine Of Yeshiva University TM4 conditional shuttle phasmids and uses thereof
US6387694B1 (en) 1998-04-03 2002-05-14 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial isocitrate lyase gene and uses thereof
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US7022320B1 (en) * 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
CN1367875A (zh) * 1999-07-08 2002-09-04 斯特思吉生物技术公司 活体外th1一样反应的诱导方法
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1253939B1 (de) 2000-01-14 2009-08-05 Whitehead Institute For Biomedical Research Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
US6471967B1 (en) 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
ATE526994T1 (de) * 2000-06-20 2011-10-15 Corixa Corp Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
ATE326236T1 (de) * 2000-06-26 2006-06-15 Stressgen Biotechnologies Corp Hpv-e7 zur behandlung von menschlichem papillomavirus
ATE357461T1 (de) 2000-08-25 2007-04-15 Aventis Pasteur Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
AU2002211201B2 (en) 2000-11-02 2007-05-31 The National University Of Singapore aopB Gene, protein, homologs, fragments and variants thereof, and their use for cell surface display
WO2002062959A2 (en) * 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) * 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2003070164A2 (en) * 2002-02-19 2003-08-28 Albert Einstein College Of Medicine Of Yeshiva University Attenuated mycobacterium tuberculosis vaccines
US7758874B2 (en) * 2002-02-19 2010-07-20 Albert Einstein College Of Medicine Of Yeshiva University Attenuated Mycobacterium tuberculosis vaccines
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
DE60319822T2 (de) * 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
WO2004016280A1 (ja) * 2002-08-16 2004-02-26 Japan Science And Technology Agency 組換えｂｃｇワクチン
WO2004046346A2 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
WO2004066928A2 (en) * 2003-01-24 2004-08-12 Albert Einstein College Of Medicine Of Yeshiva University Use of mycobacterial vaccines in cd4+ or cd8+ lymphocyte-deficient mammals
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
WO2007121193A1 (en) * 2006-04-10 2007-10-25 The Regents Of The University Of California Growth regulatable recombinant bcg immunogenic compositions
US7622107B2 (en) * 2003-10-16 2009-11-24 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
WO2007121194A1 (en) * 2006-04-10 2007-10-25 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US8383132B2 (en) * 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2006055024A2 (en) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
US7998471B2 (en) * 2005-01-12 2011-08-16 Albert Einstein College Of Medicine Of Yeshiva University Mycobacteria expressing HIV-1 and malaria antigens
WO2006076519A2 (en) * 2005-01-12 2006-07-20 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial mutants affecting host apoptosis
AU2006206851B2 (en) 2005-01-18 2010-12-16 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Mycobacteria with mannose cap-deficient lipoarabinomannan
JP2009502747A (ja) * 2005-07-14 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア １−メチル−ピラゾール−４−イルカルボキシアニリド類に基づく殺菌性混合物
WO2007063075A1 (en) 2005-11-29 2007-06-07 Actogenix Nv Induction of mucosal tolerance to antigens
US8168421B2 (en) * 2005-12-09 2012-05-01 University Of Georgia Research Foundation, Inc. Microbial vaccine and vaccine vector
EP1981964B1 (de) * 2006-01-12 2014-04-30 ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, a division of YESHIVA UNIVERSITY Mykobakterielle seca2-mutanten
CA3037889C (en) 2007-01-25 2022-09-13 Intrexon Actobiotics Nv Treatment of immune disease by mucosal delivery of antigens
WO2009008912A2 (en) 2007-03-19 2009-01-15 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial mutants inducing il-12
JP2010525812A (ja) 2007-05-02 2010-07-29 メリアル リミテッド 発現及び安定性が改善されたｄｎａプラスミド
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
MX2011006922A (es) 2008-12-24 2012-06-12 Netherlands Vaccine Inst Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia.
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
EP2675474B1 (de) 2011-02-15 2019-01-16 Vaxiion Therapeutics, LLC Therapeutische zusammensetzungen und verfahren für auf antikörper- und fc-haltigen molekülen basierende gezielte verabreichung bioaktiver moleküle durch bakterienminizellen
WO2013022991A2 (en) 2011-08-08 2013-02-14 Curelab Oncology, Inc. Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
WO2013059616A1 (en) * 2011-10-21 2013-04-25 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteriophages for delivery of nucleic acids of interest into mycobacteria
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
US20150211012A1 (en) 2012-08-31 2015-07-30 Laboratorios Del Dr. Esteve S.A. Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine
DK178233B1 (en) 2012-09-17 2015-09-14 Novartis Tiergesundheit Ag Fiskevaccine
WO2014070975A1 (en) 2012-11-02 2014-05-08 Novartis Ag Flavivirus associated with theiler's disease
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
RU2016128557A (ru) 2013-12-29 2018-02-01 Кьюрлаб Онколоджи, Инк. МЕТОДЫ И КОМПОЗИЦИИ, СВЯЗАННЫЕ С p62 / SQSTM1, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ВОСПАЛЕНИЕМ
CN107074947B (zh) 2014-08-05 2021-04-09 马布奎斯特公司 结合至pd-1的免疫试剂
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents
EP3964529A1 (de) 2016-01-22 2022-03-09 Mabquest SA Nicht-blockierende pd1 spezifische antikörper
CN109312409A (zh) * 2016-03-31 2019-02-05 金山大学,约翰内斯堡 耻垢分枝杆菌的遗传修饰株
EP3478825A4 (de) * 2016-06-30 2019-12-25 Technology Innovation Momentum Fund (Israel) Limited Partnership Bakteriophage varianten mit erweitertem wirtsbereich, verfahren zur herstellung und verwendungen davon zur umwandlung von nukleinsäuren in interessante wirte
US11944679B2 (en) 2017-03-14 2024-04-02 The Regents Of The University Of California Genome-wide identification of immune evasion functions in a virus
CN109825497A (zh) * 2019-01-25 2019-05-31 石河子大学 一种新型结核杆菌融合菌株的制备方法及其应用
JP2022541900A (ja) 2019-07-15 2022-09-28 ローザンヌ ユニヴァーシティ ホスピタル Ｈｉｖ結合剤
TW202206098A (zh) 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
CA3230802A1 (en) 2021-08-31 2023-03-09 Zoetis Services Llc Attenuated alphavirus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59205983A (ja) * 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
US4743546A (en) * 1985-02-13 1988-05-10 Biotechnica International, Inc. Controlled gene excision
US4906742A (en) * 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
EP0681026A1 (de) * 1987-03-02 1995-11-08 Whitehead Institute For Biomedical Research Rekombinant-mykobakterielle Impfstoffe

Also Published As

Publication number Publication date
US6270776B1 (en) 2001-08-07
AU3867789A (en) 1990-02-05
US5968733A (en) 1999-10-19
JP3485916B2 (ja) 2004-01-13
CA1339526C (en) 1997-11-04
US5854055A (en) 1998-12-29
DE68929507T2 (de) 2004-09-23
EP0424437A1 (de) 1991-05-02
US6372478B1 (en) 2002-04-16
US5504005A (en) 1996-04-02
WO1990000594A2 (en) 1990-01-25
JP2000350578A (ja) 2000-12-19
ATE256730T1 (de) 2004-01-15
EP0424437B1 (de) 2003-12-17
WO1990000594A3 (en) 1990-05-03
JPH04500305A (ja) 1992-01-23

Similar Documents

Publication Publication Date Title
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
KR940010865B1 (ko) 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법
Srivastava et al. Tumor rejection antigens of chemically induced sarcomas of inbred mice.
US5591632A (en) Recombinant BCG
EP0856059B1 (de) Verfahren zur herstellung von rekombinanten plasmiden
ATE353362T1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
DE69034100D1 (de) Verktorvermittelte genominsertion und expression von dna in bcg
DE3854840D1 (de) Rekombinant-mykobakterielle impfstoffe
WO1995016048A3 (en) Recombinant protein production in bovine adenovirus expression vector system
DK0551401T3 (da) Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet
CA2209360A1 (en) Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
IL133056A (en) Polypeptide containing an immunogenic portion of an m. tuberculosis antigen, a variant thereof and pharmaceutical compositions containing same
JP2001514000A5 (de)
EP0068693A3 (de) Herstellung eines Maul- und Klauenseuche Impfstoffes aus mikrobiellen exprimierten Antigenen
Büttner et al. The photosystem I-like P840-reaction center of green S-bacteria is a homodimer
AU669483B2 (en) Nucleotide sequences and resistance proteins cycloheximide
MY135991A (en) A vaccine-induced hepatits b viral strain and uses thereof
WO2003097814A3 (en) Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
Kerksiek et al. Variable immunodominance hierarchies for H2-M3-restricted N-formyl peptides following bacterial infection
EP1233024A3 (de) 25466, ein Mitglied aus der Familie menschlicher Transportproteine und seine Anwendungen
Yeung et al. Production of rabbit polyclonal antibody against apobec-1 by genetic immunization
Tanaka et al. Heterogeneity of the principal sigma factor in Escherichia coli: The rpoS gene product, sigma super (38), is a second principal sigma factor of RNA polymerase in stationary-phase Escherichia coli.
EP0272894A2 (de) Rekombinantes menschliches Lymphotoxin
KR930701600A (ko) 안정적이고 생물활성적인 변형된 소마토트로핀

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee